GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, reported its financial results for the year ended December 31, 2025, and provided an update on its key programs. The company disclosed a net loss of $21.5 million for 2025, compared to $25.0 million in 2024, with revenue from government contracts decreasing to $2.5 million from $4.0 million. Research and development expenses fell to $18.1 million from $23.7 million, primarily due to the termination of a BARDA contract and reduced costs for certain programs. As of December 31, 2025, GeoVax held $3.1 million in cash.
The most significant development is the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. GeoVax received formal Scientific Advice from the European Medicines Agency (EMA) supporting a streamlined development pathway, including a single Phase 3 immuno-bridging study without prior Phase 1 or 2 trials. The company plans to initiate this pivotal Phase 3 trial in the second half of 2026. Additionally, GeoVax completed cGMP manufacturing and fill-finish of clinical-grade GEO-MVA, positioning the company for clinical supply and potential commercialization. CEO David Dodd stated, “We believe GEO-MVA represents a critically important opportunity to eliminate the current global supply constraint in orthopoxvirus vaccines, while supporting broader public health preparedness and biosecurity objectives.”
The company is positioning GEO-MVA to meet policy-driven demand for diversified and domestic vaccine supply, especially given recurring mpox outbreaks and depleted government stockpiles. GeoVax is engaging with international regulatory and governmental stakeholders to align GEO-MVA with public health preparedness frameworks. Beyond GEO-MVA, GeoVax is advancing other pipeline programs. GEO-CM04S1, a COVID-19 vaccine candidate, is progressing through Phase 2 trials in immunocompromised populations, with data readouts expected in 2026. The Gedeptin oncology program, targeting head and neck cancer, completed a Phase 1/2 trial, and an exclusive license agreement with Emory University was entered to support combination use with immune checkpoint inhibitors. A Phase 2 trial for first-line treatment is planned for 2027.
The financial results reflect the company's focus on GEO-MVA and the termination of the BARDA contract. General and administrative expenses increased to $6.0 million from $5.4 million, attributed to higher personnel costs and investor relations. GeoVax’s cash position decreased to $3.1 million from $5.5 million at the end of 2024. The company believes its current resources are sufficient to fund operations into the near term, but additional capital will be required to complete the Phase 3 trial and other development activities. For more information, visit GeoVax's website.
The implications of this announcement are significant for global health security. If GEO-MVA successfully completes its Phase 3 trial and gains regulatory approval, it could provide a critical alternative supply source for orthopoxvirus vaccines, addressing current shortages and reducing dependence on a single foreign manufacturer. This would enhance pandemic preparedness for mpox and smallpox, which remain concerns due to potential bioterrorism or natural outbreaks. GeoVax's progress also underscores the importance of public-private partnerships in advancing vaccines for high-consequence infectious diseases, as evidenced by the earlier BARDA support. However, the company faces financial challenges and must secure additional funding to continue development, highlighting the risks inherent in biotechnology investments.
